Aims/hypothesis Breakdown of the inner blood-retinal barrier (BRB) is an early event in the pathogenesis of diabetic macular oedema, that eventually leads to vision loss. We have previously shown that diabetes causes an imbalance of nerve growth factor (NGF) isoforms resulting in accumulation of its precursor proNGF and upregulation of the p75 neurotrophin receptor (p75 NTR ), with consequent increases in the activation of Ras homologue gene family, member A (RhoA). We also showed that genetic deletion of p75 NTR in diabetes preserved the BRB and prevented inflammatory mediators in retinas. This study aims to examine the therapeutic potential of LM11A-31, a small-molecule p75 NTR modulator and proNGF antagonist, in preventing diabetesinduced BRB breakdown. The study also examined the role of p75 NTR /RhoA downstream signalling in mediating cell permeability.
Introduction
Diabetic retinopathy is a diabetic microvascular complication that threatens sight and ultimately leads to blindness in working-age individuals in the USA [1] . While~34.6% of individuals with diabetes have a degree of retinopathy, 6.8% are diagnosed with early diabetic macular oedema (DMO) and 7% with proliferative diabetic retinopathy (PDR) [2] . Inflammation and deterioration of the inner blood-retinal barrier (BRB) and capillary leakage have been identified in both DMO and PDR. Current therapies include laser photocoagulation as well as intravitreal injections of corticosteroids and anti-vascular endothelial growth factor (VEGF) (reviewed in [1] ). However, the invasiveness of the repeated ocular injection, risk of neuronal toxicity and atrophy and increased thromboembolism impose serious limitations [3] . On the other hand, several systemic orally administered drugs failed repeatedly in clinical trials [4] [5] [6] [7] . Hence, there is a need to identify specific targets that are 'upstream' of the terminal effectors involved in diabetes-associated visual outcomes.
Our group discovered that diabetes-associated oxidative stress impairs the processing and maturation of nerve growth factor (NGF) resulting in accumulation of its precursor proNGF in individuals with type 1 diabetes [8] and type 2 diabetes [9] as well as in experimental models of diabetes [10, 11] . This proNGF/NGF imbalance coincided with significant increases in
Research in context
What is already known about this subject?
Diabetic macular oedema is closely linked to breakdown of the blood-retinal barrier (BRB) and predisposes individuals with diabetes to vision loss. Therapeutic options are limited and invasive Our previous work using animal models of diabetes and clinical samples from individuals with diabetes has shown that the nerve growth factor precursor proNGF, and its receptor p75 NTR , are implicated in retinal diabetic complications. The proNGF/p75 NTR signalling pathway in diabetes also correlates with activation of RhoA
We have also shown that genetic deletion of p75 NTR in diabetes preserves BRB integrity and attenuates inflammation in retinas from models of diabetes
What is the key question?
Can modulating p75 NTR activity using LM11A-31, a small-molecule p75 NTR modulator, be effective therapeutically in preventing diabetes-induced BRB breakdown and what is the role of p75 NTR /RhoA downstream signalling in mediating vascular permeability?
What are the new findings?
In vivo, using a streptozotocin-induced mouse model of diabetes, diabetes triggered BRB breakdown and increased circulatory and retinal IL-1 and TNF-expression. This coincided with increases in proNGF and VEGF and activation of RhoA
Interventional modulation of p75 NTR using LM11A-31 significantly mitigated diabetes-induced retinal proNGF, VEGF, IL-1 and TNF-and preserved BRB integrity
How might this impact on clinical practice in the foreseeable future?
LM11A-31, an orally bioavailable receptor modulator, may offer an effective, safe and non-invasive therapeutic strategy for treating macular oedema, a major cause of blindness in diabetes the level and cleavage/shedding of the p75 neurotrophin receptor (p75 NTR ) in vitreous and serum of individuals with diabetic retinopathy [9, 12] . p75 NTR , a member of the TNF-α receptor superfamily, can bind to all neurotrophins and has particularly high affinity for proNGF (reviewed in [13] ). The p75 NTR receptor undergoes γ-secretase intramembrane proteolysis to release its intracellular domain, which can recruit various adaptor proteins to activate multiple pathways including those involved in inflammation, cell motility, degeneration and cell death [13] . Rho GTPases are a subfamily of the Ras superfamily proteins that play a critical role in the regulation of cell motility and migration [14] . We have also shown that diabetes and overexpression of proNGF activate Ras homologue gene family, member A (RhoA) kinase, coinciding with BRB breakdown [8] .
We and others showed that the proNGF-p75 NTR pathway is upstream of TNF-α and IL-1β production in the retina [10, 15, 16] . These studies have identified that the proinflammatory action of proNGF occurs via activation of p75 NTR in retinal glial Muller cells [10, 11, [15] [16] [17] . Moreover, genetic deletion or silencing of p75 NTR prevented diabetes-induced short-term neurodegeneration [18] , inflammation and BRB breakdown [10] and long-term effects including formation of occluded acellular capillaries and pericyte loss [11, 19] . While these findings provide a solid rationale for therapeutic targeting of p75 NTR , the studies utilised molecular tools. Therefore, there is a pressing need to develop and test specific p75 NTR pharmacological modulators that could be formulated into a viable pharmaceutical option.
The aim of this study is to examine the impact of systemic administration of LM11A-31, a water-soluble, non-peptide, small-molecule p75 NTR modulator [20] with high bloodbrain barrier permeability [21] , on the vascular integrity of the retina in diabetes. LM11A-31 functions as a p75 NTR modulator by downregulating p75 NTR degenerative signalling in the absence of the proNGF ligand [22] . In the presence of proNGF, it functions as an antagonist to block proNGF binding and activation of p75 NTR degenerative signalling [23] . Markers of inflammation, the ratio of NGF/proNGF, and retinal vascular permeability were assessed in a mouse model of diabetes wherein mice were treated with LM11A-31 or vehicle. These in vivo studies were complemented with in vitro studies that examined, for the first time, the extent and the molecular mechanism by which proNGF alters retinal barrier function and contributes to retinal vascular permeability.
Methods
Animals All procedures were performed in accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research, and the Charlie Norwood VA Medical Center Animal Care and Use Committee (ACORP no. 16-01-088).
Induction of diabetes Male 8-week-old C57BL/6 J mice (~25 g) were purchased from Jackson laboratory (Bar Harbor, ME, USA) and kept under controlled temperature (21-23°C) and lighting conditions (12 h light/12 h dark cycle). Animals were provided with access to food and water ad libitum. Mice were blindly coded and randomly assigned into four groups: two control groups, receiving either vehicle (saline [NaCl 154 mmol/l]) or LM11A-31 (2-amino-3-methyl-pentanoic acid [2-morpholin-4-yl-ethyl]-amide) and two diabetic groups receiving either vehicle or LM11A-31. Mice were rendered diabetic by five consecutive intraperitoneal injections of streptozotocin, 50 mg/kg (Sigma, St Louis, MO, USA) in 10 mmol/l citrate buffer. Blood glucose levels were assessed and hyperglycaemia was defined by glucose >12.5 mmol/l. Two weeks after the confirmation of diabetes, one set of control and diabetic mice received non-peptide, small-molecule LM11A-31 (50 mg/kg per mouse) or vehicle (saline) every 48 h by oral gavage for 4 weeks. Experiments were carried out in duplication on each of the four animal sets and body weight was recorded weekly. Mice were killed after 6 weeks of diabetes, eyes were enucleated and microvasculature was isolated from pial blood vessels as described previously [24] .
Measurement of serum IL-1β and TNF-α levels Serum levels of IL-1β and TNF-α were determined using a high sensitivity ELISA kit (catalogue no. 50-112-9749 for IL-1β) and (catalogue no. 50-112-8954 for TNF-α) from eBioscience (Fisher Scientific, Waltham, MA, USA), according to manufacturer instructions and as described previously by our group [25] . Inflammatory mediators were expressed as pg/ml and normalised to protein concentration in each sample.
Vascular permeability To determine BRB breakdown, mice received injections of 100 μl of 5 mg/ml BSA-conjugated AlexaFluor-488 green fluoresce (Invitrogen; Thermo-Fisher Scientific, Waltham, MA, USA) into the jugular vein. After 20 min, mice were killed. Retinas were snap-frozen in liquid nitrogen and blood was collected from the abdominal inferior vena cava. Fluorescence of retinal lysate and serum from the same mouse was measured using a plate reader (Synergy2; BioTek, Winooski, VT, USA) at excitation 490 nm and emission 525 nm. The average retinal fluorescence intensity was normalised to protein content and to serum fluorescence intensity for each mouse, as described previously [10] .
Human retinal endothelial cell culture Human retinal endothelial (HRE) cells and supplies were purchased from Cell Systems Corporations (Kirkland, WA, USA) and VEC Technology (Rensselaer, NY, USA). Experiments were performed using cells between passages 4 and 6, at 37°C, in a humidified atmosphere of 5% CO 2 . The authentication of HRE and confirmation of mycoplasma-free status were provided by Cell Systems. Cells were randomised and switched to serum-free medium containing 10% MCDB131 complete medium (VEC Technology, Rensselaer, NY, USA) overnight, prior to treatment with cleavage-resistant human mutant proNGF (10 ng, hm-proNGF; Alomone, Jerusalem, Israel) in the presence or absence of the p75 NTR modulator LM11A-31 (200 nmol/l) or the Rho kinase inhibitor Y-26732 (10 μmol/l). Cell cultures were run in duplicate for each condition and each experiment was repeated at least three times.
Cell permeability assay HRE cells grown to confluence on Transwell inserts (Corning, NY, USA) were switched to serum-free culture media. Transport assays were performed using 70 kDa fluorescein isothiocyanate (FITC)-dextran to mimic paracellular flux of an albumin-sized molecule, according to a previously described protocol [26] . FITC-dextran (1 mg/ml) was added to the luminal compartment after which 50 μl samples were collected from abluminal compartment every 60 min. Cell permeability was proportional to the rate of accumulation of FITC-dextran in the abluminal compartment. The rate of flux was calculated over the 4 h time course using the following formula:
where Po is the rate of flux in cm/s, F L is basolateral fluorescence, F A is apical fluorescence, Δt is change in time, A is surface area of the filter and V A is volume of the basolateral chamber [26] . Viability of HRE cells was determined by incubating cells for 4 h at 37°C with 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in PBS. MTT, a yellow dye, is reduced to purple formazan in living cells. MTT was dissolved in acid isopropanol (1:9 of 1 mmol/l HCl/isopropanol). Absorbance was measured at 540 nm and 690 nm using a microplate reader (Bio-Tek), as described previously [18] .
G-LISA assay for Rac-1 and RhoA in cell culture and microvascular preparations Detection of the activity of RhoA-GTPase (catalogue no. BK121) and Ras-related C 3 botulinum toxin substrate 1 (Rac1; catalogue no. BK126) was performed using a G-LISA kit from Cytoskeleton (Denver, CO, USA), according to the manufacture protocol. Tissues were homogenised and protein concentration was determined using the reagents provided in the kit. Bound active RhoA or active Rac1 was detected using a specific antibody and luminescence. The luminescence signal was quantified using a microplate reader (Synergy2; BioTek). RhoA-GTPase or Rac1 activity (relative luminescence units) values were normalised to protein content (mg) and then normalised to the average of the control group.
Western blot assay Retinal samples were homogenised and 30 μg protein was separated by SDS-PAGE [12] . Antibodies, which are listed in ESM Table 1 , were validated by the manufacturer. The primary antibody was detected using horseradish peroxidase-conjugated sheep anti-rabbit or anti-mouse antibody (GE Healthcare, Piscataway, NJ, USA) and enhanced chemiluminescence (Pierce; Thermo-Fisher Scientific, CA, USA). The films were scanned with FluorChem FC3 (ProteinSimple, San Jose, CA, USA) and band intensity was quantified using Fiji densitometry software version-1 (https:// imagej.net/Fiji/Downloads), normalised to internal controls and expressed as relative optical density.
Immunofluorescence was performed as described previously [19] . HRE cells were fixed with 2% (wt/vol.) paraformaldehyde and incubated with blocking buffer followed by (1:100) zonula occludens-1 (ZO-1) antibody and a secondary antibody conjugated to Texas Red (ESM Table 1 ). Additional sets of cells were stained with (1:200) Oregon Green 448 phalloidin to detect stress fibre formation. Specimens were covered with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Micrographs were taken using a fluorescence microscope (Axiovert-200; Carl Zeiss, Thornwood, NY, USA) at ×20 magnification.
Statistical analysis Results are expressed as mean ± SEM and the data were evaluated for normality and processed for statistical analysis using the unpaired Student's t test, one-way ANOVA or two-way ANOVA. There was no intentional removal of any outcome measures. The Z-score test was used for the detection of outliers. Bonferroni post-multiple comparisons test was used to assess significant differences among individual groups. Analysis was performed using Graph-Pad prism software, version 6 (https://download.cnet.com/ GraphPad-Prism/3000-2053_4-8453.html). Significance was set at p < 0.05.
Results

Modulation of p75
NTR using LM11A-31 did not alter blood glucose level or body weight As shown in ESM Fig. 1 , blood glucose levels were significantly higher in diabetic vs control mice at 6 weeks post-induction of diabetes. There was no significant difference in body weight between the control group and diabetic group. Treatment with LM11A-31 did not affect body weight or blood glucose level in either the control group or in the diabetic group.
Treatment with LM11A-31 restored the NGF/proNGF ratio in retinas from diabetic mice Our group has previously shown that the diabetic state induces a significant increase in proNGF with a decrease in NGF level [9] . Consistent with this, diabetic mouse retinas showed significant increases in proNGF (Fig.  1a , b) as well as significant decrease in retinal NGF levels (Fig. 1a, c) . Consequently, the proNGF/NGF ratio was significantly elevated in retinas from diabetic mice as compared with those from control mice (Fig. 1d ). Interventional treatment of diabetic mice with LM11A-31 prevented the further increase in proNGF and preserved NGF level (Fig. 1a-c ) and restored the retinal proNGF/NGF ratio (Fig. 1d) .
Treatment with LM11A-31 mitigated diabetes-induced systemic and retinal inflammation Diabetes is perceived as a low-grade chronic systemic inflammation [27] . Therefore, we examined expression of inflammatory mediators in the mouse retina and serum. Diabetes significantly increased expression of retinal TNF-α (twofold, Fig. 2a ) and IL-1β (twofold, Fig. 2b ) as compared with control mice. Oral treatment of diabetic mice with LM11A-31 significantly attenuated diabetes-induced increases in retinal expression of TNF-α and IL-1β (Fig. 2a, b) . Indeed, diabetic mice displayed significantly increased levels of serum TNF-α (5.5-fold, Fig. 2c ) and IL-1β (ninefold, Fig. 2d ) compared with control mice. Oral treatment with LM11A-31 significantly decreased diabetes-induced increases in serum TNF-α and IL-1β (Fig.  2c, d ) but had no effect on levels of these inflammatory mediators in control mice.
Treatment with LM11A-31 prevents diabetes-induced retinal vascular permeability Increases in VEGF have been positively correlated with diabetic retinopathy. Therefore, we examined the impact of modulating p75 NTR on VEGF expression. As shown in Fig. 3a , retinal expression of VEGF was significantly increased in diabetic vs control mice. Oral treatment with LM11A-31 led to a significant decrease in retinal VEGF expression in the diabetic mouse (Fig. 3a) . Retinal vascular permeability was assessed by extravasation of BSA-conjugated AlexaFluor-488. After 6 weeks of diabetes, there was significant increase in retinal vascular permeability (~twofold) in the retinas from diabetic mice, as compared with control mouse retinas (Fig. 3b) . Oral treatment with LM11A-31 significantly decreased the diabetes-induced increase in vascular permeability compared with vehicle treatment (Fig. 3b) . These results support a pivotal role for upregulated proNGF/ p75 NTR in mediating diabetes-induced retinal inflammation and vascular permeability.
ProNGF triggers barrier dysfunction independent of inflammation or cell death in HRE cells To examine whether proNGF causes barrier dysfunction via direct activation of endothelial p75 NTR , HRE cells were treated with hmproNGF, which is cleavage-resistant. For cell permeability assays, HRE cells were grown on Transwell inserts to complete confluence then switched to serum-free medium and challenged with various concentrations of hm-proNGF (1, 10, 20, 50 ng/ml). Treatment of HRE cultures with hmproNGF induced cell permeability and barrier dysfunction in a bell-shaped manner, where 10 ng/ml caused the highest cell permeability when compared with cells treated with 1 ng/ml, 50 ng/ml or untreated control (Fig. 4a) . The viability of HRE cells was examined using the MTT assay using similar doses of hm-proNGF that were used in permeability assay. The results showed that hm-proNGF, up to 50 ng/ml, did not affect viability of HRE compared with untreated controls (Fig. 4b) . Because proNGF is a known upstream inducer of inflammatory mediators in vivo [13] , we next examined its proinflammatory effect in HRE cells. Treatment with hm-proNGF did not significantly affect expression of VEGF or TNF-α in HRE cells when compared with untreated controls (Fig. 4c ). Yet, within the same time-frame (6 h), hm-proNGF (10 ng/ml) significantly decreased expression of the tight junction proteins ZO-1 (~45%) and claudin-5 (~40%) vs untreated cells (Fig. 4d) .
ProNGF induced HRE cell permeability in a p75 NTR -dependent manner A representative graph is shown in Fig. 5a to demonstrate how cell permeability is proportional to the rate of accumulation of FITC-dextran in the abluminal compartment over time up to 4 h. The rate of flux was calculated according to the previously published formula [26] and the results of multiple runs were combined. As shown in Fig. 5b , treatment with hm-proNGF (10 ng/ml) significantly induced cell permeability (1.4-fold) compared with untreated control. Prior treatment with LM11A-31 significantly attenuated hm-proNGFmediated HRE cell permeability but did not affect permeability of untreated control cells (Fig. 5b) .
Diabetes and proNGF cause activation of RhoA kinase in a p75 NTR -dependent manner Next, we examined the effect of modulating p75
NTR signalling on RhoA kinase activation in vasculature. Mechanisms through which p75 NTR regulates RhoA kinase activation have been characterised previously [28] . Due to sample size limitations, activation of RhoA and RAC-1 were assessed using the G-LISA assay. In microvasculature isolated from diabetic mice, there was significant activation of RAC-1 (ESM Fig. 2 ) and significant (2.2-fold) increase in active RhoA kinase (Fig. 6a ) compared with control mouse microvasculature. Treatment with LM11A-31 blunted the increase in RhoA kinase and RAC-1 activity in the diabetic mice. In vitro, we examined the impact of hmproNGF (10 ng/ml) on the activation of RhoA kinase in HRE cells. In parallel to the diabetic condition, hm-proNGF treatment caused significant (1.4-fold) activation of RhoA compared with control cultures (Fig. 6b) . The Rho kinaseactivating effect of hm-proNGF was significantly ameliorated by prior treatment with LM11A-31. attenuated hm-proNGF-mediated cell permeability (Fig. 7b) . These results support the notion that the p75 NTR /RhoA kinase signalling pathway contributes to proNGF-induced vascular permeability.
ProNGF induced occludin phosphorylation and altered distribution of tight junction proteins in a p75
NTR -dependent manner Next we examined phosphorylation of occludin at serine 490 (p-occludin S490 ), a perquisite for ubiquitination and degradation of the tight junction proteins. Western blot analysis revealed that treatment of HRE cells with hm-proNGF induced significant activation of p-occludin S490 (1.7-fold) and that this activation was blocked by p75 NTR modulation using LM11A-31 (Fig. 8a) . Immunofluorescence assays showed that ZO-1, a tight junction-associated protein, was localised mostly in discrete, continuous lines in control untreated HRE cells and was redistributed in a punctate and discontinuous pattern in hm-proNGF-treated cells (white arrows, Fig. 8b ). The proNGF-mediated redistribution of ZO-1 was mitigated by LM11A-31 treatment (Fig. 8b) . Treatment with hmproNGF also induced intense F-actin stress fibre formation (white arrows, Fig. 8c ) when compared with untreated controls; this effect was also mitigated by treatment with LM11A-31.
Discussion
Increases in VEGF levels have been closely associated with breakdown of the inner BRB in DMO and to pathological angiogenic response in PDR. Interestingly, individuals with DMO require multiple and repeated intraocular injections of anti-VEGF therapy while those with PDR benefit from fewer anti-VEGF injections [29] . Therefore, it is conceivable to hypothesise that multiple factors other than VEGF can contribute to vascular permeability in DMO. The current study demonstrated the extent and the possible mechanisms by which the proNGF-p75 NTR pathway contributes to diabetesassociated systemic inflammation, upregulated VEGF and retinal vascular permeability (a hallmark of DMO). Moreover, the findings here support a potential novel therapeutic approach based on pharmacological modulation of p75 NTR using the orally bioavailable compound LM11A-31 to prevent early features of DMO. LM11A-31 (2-amino-3-methylpentanoic acid [2-morpholin-4-yl-ethyl]-amide) is a watersoluble isoleucine derivative. LM11A-31 functions as a ligand with relatively high specificity to p75 NTR , as demonstrated by the complete loss of its protective activity in cultures of p75 NTR−/− neurons, which lack p75 NTR [22, 23] . It has proven effective in slowing or reversing neurodegeneration and impaired cognitive behaviour in animal studies [20, 30, 31] . LM11A-31 reduced neuro-inflammation occurring in a Huntington's disease mouse model [32] and microglial activation in an Alzheimer's disease model [33] . At the dose used (50 mg/kg), LM11A-31 has been shown to cross the bloodbrain barrier following oral administration [21] . Screening of LM11A-31 binding in a screening CEREP panel to identify alternative target receptors was negative [34] . To date, alternative targets or off-target effects have not been identified. LM11A-31 was approved by the US Food and Drug Administration as an investigational new drug, successfully completed a phase I safety trial in normal young and elderly individuals and is currently undergoing evaluation in a phase 2a exploratory endpoint trial in Alzheimer's disease (ClinTrials.gov registration no. NCT03069014). While the neuroprotective effects of LM11A-31 have been well documented, we believe that this is the first report in which the vascular protective effects of LM11A-31 in the retina in diabetes have been examined and that demonstrates it properties of preventing early inflammation, mitigating VEGF expression and preventing retinal vascular permeability. In the current study, 6 weeks of diabetes in mice caused imbalance in NGF homeostasis manifested by significant increases in proNGF and decreases in NGF (Fig. 1) . These results lend further support to previous reports showing that diabetes impaired maturation of neurotrophins, as demonstrated by low levels of mature NGF and brain-derived neurotrophic factor (BDNF) in vitreal samples from individuals with PDR [8, 9, 35] , as well as in preterm infants who experienced proliferative retinopathy [36] . Treatment of diabetic mice with LM11A-31, a pharmacological modulator of p75 NTR , prevented the significant increase in proNGF and restored the balance between NGF and proNGF levels.
These results concurred with prior reports showing that deletion of p75 NTR prevented diabetes-induced imbalance of the NGF/proNGF ratio [10, 11] and prevented the increase in proNGF in an ischaemic retinopathy model [15, 37] . Moreover, LM11A-31 promoted survival rate of oligodendrocytes and functional recovery after spinal cord injury, in part through blocking proNGF effects and its binding to p75 NTR [21] . The mechanisms by which modulation of p75 NTR might normalise the NGF/proNGF ratio remain to be established in future studies.
In the retina, Muller cells are the main glia, secreting vasopermeability factors such as VEGF and inflammatory mediators including TNF-α and IL-1β, which can regulate vascular permeability under pathological conditions (reviewed in [38] ). Our findings clearly demonstrate that treatment of diabetic animals with LM11A-31 mitigated the increase in inflammatory mediators but did not deplete retinal VEGF expression (Fig. 3) . In parallel, findings from the current study showed significant increases in TNF-α and IL-1β in serum and retinas isolated from diabetic animals but not from those treated with LM11A-31. These results lend further support to prior reports showing that diabetes-induced upregulation of proNGF and p75 NTR coincided with expression of inflammatory mediators and retinal vascular permeability [9, 10, 15] . The diabetes-associated increase in serum levels of TNF-α and IL-1β is intriguing as it might reflect production of inflammatory mediators by peripheral circulatory cells and/ or leakage from affected organs. In support of the notion that p75 NTR signalling can contribute to peripheral circulatory inflammation are the findings that LM11A-31 abolished proNGF-induced production of IL-6 in mononuclear cells isolated from individuals with arthritis [39] . Our findings lend further support to prior reports demonstrating the antiinflammatory benefits of blocking p75 NTR activity in reducing the number and infiltration of proinflammatory peripheral monocytes in brain injury in vivo and in vitro [40, 41] . While a growing body of evidence supports the finding that activation of the proNGF-p75 NTR pathway is an upstream hub for release of inflammatory mediators, we believe that this is the first study showing that systemic modulation of p75 NTR using LM11A-31 prevents diabetes-induced circulatory and retinal inflammation.
The above results highlight the anti-inflammatory role attained by modulating proNGF/p75 NTR using LM11A-31 and the resulting barrier-preserving effects achieved in vivo. Nevertheless, whether accumulated glial proNGF can directly trigger p75 NTR signalling on endothelial cells causing barrier dysfunction remains unknown. Due to the complex and associative nature of in vivo studies, we switched to an in vitro model utilising HRE cells that were probed with a mutant NTR using LM11A-31 significantly mitigated the diabetes-induced increase in RhoA kinase activity. (b) G-LISA assay in HRE cells showed that 10 ng/ml hm-proNGF induced a significant increase in active RhoA kinase as compared with controls. Prior treatment with LM11A-31 blocked the effect of hm-proNGF on RhoA kinase activity (n = 4-5). Activity is shown as relative luminescence units normalised to protein content (mg) and then normalised to the average of the control group. *p < 0.05 vs all other groups, two-way ANOVA form of human proNGF that is cleavage resistant. Here, we report for the first time that relatively low levels of proNGF can directly trigger barrier dysfunction in HRE cells and cause significant reductions in expression of tight junction proteins such as ZO-1 and claudin-5 vs untreated controls (Fig. 4) . Examination of different concentrations of proNGF produced a bell-shaped curve in which escalating concentrations (1, 10 and 20 ng/ml) produced significant barrier disruption while a higher level (50 ng/ml) did not. These results are in agreement with a prior observation suggesting that proNGF at a higher level can bind and activate tropomyosin-related receptor A (TrkA), resulting in a different and almost opposite biological action [42] . These permeability effects were not attributed to decline in cell viability as our results showed no significant differences in cultures treated with escalating levels of proNGF up to 50 ng/ml when compared with control. Next, we evaluated whether proNGF-mediated cell permeability in vitro is associated with inflammation as observed in vivo.
Interestingly, proNGF-mediated cell permeability was not associated with significant increases in VEGF or TNF-α expression in HRE cells (Fig. 4) . The lack of inflammatory action of proNGF in endothelial cells was in agreement with previous findings [19] .
Treatment of HRE cells with LM11A-31 prevented proNGF-mediated cell permeability (Fig. 5) , confirming the barrier-preserving function of modulating p75 NTR activity that we observed in vivo (Fig. 3) . p75
NT R signals via intramembrane proteolysis to release its intracellular domain, which can recruit various adaptor proteins including RhoA [13] . The activation of RhoA in response to proNGF/p75 NTR has been well documented in neurons [43] . Prior studies demonstrated the mechanisms through which p75 NTR regulates RhoA kinase activation [28, 44] . Our results showed that treatment with LM11A-31 reduced activation of RhoA in vivo (induced by 6 weeks of diabetes in mice; Fig. 6a ) and in vitro (induced by proNGF in HRE cells; Fig. 6b ). In support, modulation of p75 NTR using LM11A-31 significantly lowered the amount of GTP-bound RhoA in rat cortical neurons [45] . Moreover, proNGF-mediated cell permeability was attenuated by using Y-26723, a Rho kinase inhibitor (Fig.  7a, b) . These results suggest that RhoA is a primary downstream target in vascular permeability observed in response to proNGF or diabetes.
Rho GTPases, particularly RhoA, RAC-1 and CDC42, are implicated in cytoskeleton regulation and cell permeability with the subsequent involvement of the tight junction proteins ZO-1 and occludin linked to the actin cytoskeleton (reviewed in [46] ). Of note, diabetes triggered activation of RhoA (Fig.  6 ) and RAC-1 (ESM Fig. 2 ), an effect that was blocked by treatment with LM11A-31. It has been shown that the Rho kinase-dependent reorganisation and accumulation of actin stress fibres occur along small focal adhesion-like structures located at the centre of endothelial cells. Our results showed that proNGF-mediated cell permeability coincided with decrease in tight junction proteins such as ZO-1 and claudin-5 ( Fig. 4) and redistribution of ZO-1 and F-actin microfilaments (Fig. 8) . In support, prior studies showed that endothelial permeability involves re-localisation of occludin and scaffold protein ZO-1 at tight junctions and also decreasing expression levels of occludin [46] . We also examined the phosphorylation of occludin at S490, which is required for occludin ubiquitination, endocytosis and endothelial permeability [47, 48] . Treatment of HRE cells with proNGF triggered occludin phosphorylation at serine 490; this was mitigated by pharmacological modulation of p75 NTR (Fig. 8) , suggesting that p75 NTR signalling is a potential underlying player regulating alteration in tight junction proteins and subsequent increased vascular permeability.
In conclusion, the mechanism through which LM11A-31 preserves BRB integrity involves modulation of the upregulated p75 Data availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
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